Simulations Plus, Inc. (NASDAQ:SLP – Get Free Report) has earned a consensus rating of “Hold” from the nine brokerages that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, six have given a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $21.50.
A number of research firms have recently weighed in on SLP. Weiss Ratings raised shares of Simulations Plus from a “sell (d-)” rating to a “sell (d)” rating in a research report on Friday, June 5th. TD Cowen decreased their target price on shares of Simulations Plus from $19.00 to $16.00 and set a “hold” rating on the stock in a research report on Friday, April 10th. Finally, Wall Street Zen cut shares of Simulations Plus from a “buy” rating to a “hold” rating in a research note on Saturday.
Get Our Latest Stock Report on Simulations Plus
Institutional Investors Weigh In On Simulations Plus
Simulations Plus Trading Up 0.3%
Simulations Plus stock opened at $16.37 on Tuesday. The stock has a 50-day moving average price of $14.88 and a 200 day moving average price of $15.56. Simulations Plus has a 52 week low of $11.09 and a 52 week high of $21.01. The stock has a market cap of $330.67 million, a PE ratio of -5.23 and a beta of 1.32.
Simulations Plus (NASDAQ:SLP – Get Free Report) last released its earnings results on Thursday, April 9th. The technology company reported $0.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.08. Simulations Plus had a negative net margin of 77.96% and a positive return on equity of 16.21%. The company had revenue of $24.29 million for the quarter, compared to analyst estimates of $21.66 million. On average, equities analysts predict that Simulations Plus will post 0.85 EPS for the current year.
Simulations Plus Company Profile
Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.
Featured Stories
- Five stocks we like better than Simulations Plus
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
- Iran Ceasefire or Not, These 3 Companies Could Win
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.
